Hexoprenaline: a Review of Its Pharmacological Properties and Therapeutic Efficacy with Particular Reference to Asthma

Overview

Journal Drugs

Specialty Pharmacology

Date 1977 Jul 1

PMID 195789

Citations 8

Authors

R M Pinder

R N Brogden

T M Speight

G S Avery

Affiliations

Soon will be listed here.

Abstract

Hexoprenaline1, N,N-[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl] hexamethyl-enediamine, sulphate is a selective beta2-adrenoreceptor agonist which is active in man as a bronchodilator by the oral or intravenous routes and by inhalation. It is indicated for use in the treatment of bronchospasm associated with obstructive airways diseases, including asthma, bronchitis and emphysema. Clinical experience and double-blind studies have established that hexoprenaline is an effective bronchodilator. It major advantage over many other many other brochodilators of equal efficacy is its generally low production of side-effects, particularly tremor, palptitations, and tachycardia. In comparative trials, it has generally been rated as superior to orciprenaline or trimetoquinol, but comparisons with salbutamol have provided equivocal results. Oral hexoprenaline was superior to fenoterol as long-term maintenance therapy is asthma, principally because its somewhat lesser bronchodilatory effects were more than compensated for by a lesser incidence of side-effects.

Citing Articles

drug repurposing using molecular docking and dynamics to target the protein interaction between the SARS-CoV-2 S-glycoprotein and the ACE2 receptor.

Hussein D, Almatrafi A, Gomaa M, Alhowsawi A, Almustafa S, Alsaihaty H F1000Res. 2024; 12:1452.

PMID: 39474132 PMC: 11519612. DOI: 10.12688/f1000research.131508.2.

The Identification of Potential Anti-Depression/Anxiety Drug Targets by Stress-Induced Rat Brain Regional Proteome and Network Analyses.

Liu N, Tu J, Yi F, Zhang X, Zhong X, Wang L Neurochem Res. 2024; 49(10):2957-2971.

PMID: 39088164 DOI: 10.1007/s11064-024-04220-x.

The Acute Effects of the Use of Salbutamol and Ipratropium on the Heart Rates of Patients With Obstructive Airway Disease.

Akhtar A, Abbas S, Zaidi S, Sohail A, Alam M, Raza L Cureus. 2023; 15(10):e46409.

PMID: 37927692 PMC: 10620622. DOI: 10.7759/cureus.46409.

Potential Inhibitors of SARS-CoV-2 Main Protease (M) Identified from the Library of FDA-Approved Drugs Using Molecular Docking Studies.

Verma D, Kapoor S, Das S, Thakur K Biomedicines. 2023; 11(1).

PMID: 36672593 PMC: 9856154. DOI: 10.3390/biomedicines11010085.

Development and Validation of a Stability-Indicating UPLC Method for the Determination of Hexoprenaline in Injectable Dosage Form Using AQbD Principles.

Afonso Urich J, Marko V, Boehm K, Lara Garcia R, Jeremic D, Paudel A Molecules. 2021; 26(21).

PMID: 34771005 PMC: 8587854. DOI: 10.3390/molecules26216597.

References

Kaik G . [(Whole body plethysmographic studies on the bronchospasmolytic effect of injectabls drugs. Comparison of aminophylline, diprophylline and hexoprenaline)]. Int J Clin Pharmacol Biopharm. 1976; 14(3):177-85. View

Fischer M . [Effects of hexoprenaline (ST 1512, Ipradol) on blood coagulation and fibrinolysis]. Wien Klin Wochenschr. 1971; 83(8):130-4. View

Pall H, Schlick W . [Spirographic results in clinical administration of hexoprenalin]. Wien Klin Wochenschr. 1971; 83(7):117-21. View

Benjamin C, van As A . Clinical trial of intravenous hexoprenaline in asthma. S Afr Med J. 1972; 46(20):599-603. View

Schindl R . [Resistance and pulse frequency in broncholytic dosage aerosols]. Wien Med Wochenschr. 1976; 126(41):589-94. View

Wilk F . [Bronchospastic states in childhood]. Wien Klin Wochenschr. 1971; 83(6):98-101. View

TITSCHER R . [Aerosols in the treatment of bronchial asthma]. Wien Klin Wochenschr. 1972; 24(50):813-4. View

Ulmer W . [Double blind trial of hexoprenaline as a bronchodilator]. Arzneimittelforschung. 1974; 24(5):840-1. View

Vermaak J, de Kock M, Joubert J . Hexoprenaline--a new bronchodilator. S Afr Med J. 1972; 46(51):1999-2001. View

10.

Lageder H, Hitzenberger G, Thoma F, Irsigler K . [Effect of hexoprenaline on blood pressure]. Int J Clin Pharmacol. 1974; 10(2):90-4. View

11.

ODonnell S, Wanstall J . Hexoprenaline: beta-adrenoreceptor selectivity in isolated tissues from the guinea-pig. Clin Exp Pharmacol Physiol. 1975; 2(6):541-7. DOI: 10.1111/j.1440-1681.1975.tb01859.x. View

12.

WITEK F . [Results of a clinical trial of a newly developped bronchospasmolytic agent (hexoprenalin, Ipradol)]. Wien Klin Wochenschr. 1971; 83(7):114-7. View

13.

de Villiers V . [Suppression of labor contractions by intravenous hexoprenaline: a preliminary investigation in the Paarl Hospital]. S Afr Med J. 1975; 49(10):345-8. View

14.

Lipshitz J, Baillie P . Uterine and cardiovascular effects of beta2-selective sympathomimetic drugs administered as an intravenous infusion. S Afr Med J. 1976; 50(49):1973-7. View

15.

KIESEWETTER E . [Effects on the circulation and tolerance of broncholytic agent ST 1512 (Hexoprenaline, Ipradol)]. Wien Klin Wochenschr. 1971; 83(6):101-4. View

16.

Leifer K, WITTIG H . Annals of allergy. Ann Allergy. 1975; 35(2):69-80. View

17.

TITSCHER R . [A new drug for chronic treatment of bronchospastic states]. Wien Med Wochenschr. 1971; 121(8):146-7. View

18.

STORMANN H, Turnheim K . [The stimulating effect of hexoprenaline on various sympathetic beta-receptors]. Arzneimittelforschung. 1973; 23(1):30-8. View

19.

Kamper B, Leodolter S, Hellmann G, Hertting G . [Pharmacokinetic studies on 3H-hexoprenaline in the rat]. Arzneimittelforschung. 1973; 23(5):721-9. View

20.

Turnheim K, KRAUPP O . Pulmonary and systemic circulatory effects and -adrenergic selectivity of hexoprenaline, salbutamol, oxyfedrine, and isoproterenol. Eur J Pharmacol. 1971; 15(2):231-9. DOI: 10.1016/0014-2999(71)90178-6. View